Adagene Inc. (NasdaqGM: ADAG)
Health Care · Biotechnology · CN
$2.74
-0.72% today · +44.5% 1Y
Adagene Inc. (NasdaqGM: ADAG) operates in the Biotechnology industry within the Health Care sector. The company is valued at $185.32M and employs 128 people.
Over the last twelve months the share price has gained 44.5%, trading between 1.30 and 4.85.
Tweenvest scores Adagene Inc. across four factors: quality 40/100, value 82/100, growth 61/100. Its strongest factor is value.
ADAG price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $185.32M
- Revenue (TTM)
- $9.29M
- P/E
- —
- EPS
- -0.39
- Dividend yield
- —
- Beta (5Y)
- 0.54
- 52-week high
- $4.85
- 52-week low
- $1.30
- Avg volume (3M)
- —
- Shares outstanding
- 67.14M
- Employees
- 128
- Next earnings
- —
About Adagene Inc.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
- ISIN
- US0053291078
- Founded
- 2011
- Listed since
- Feb 9, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Exagen Inc.NasdaqGM: XGN | $199.86M | $8.25 | -2.02% |
| Alpha Cognition Inc.NasdaqCM: ACOG | $196.87M | $8.84 | -2.21% |
| Thor Medical ASAOB: TRMED | $196.75M | Nkr4.46 | -1.00% |
| IntoCell, Inc.KOSDAQ: A287840 | $193.53M | ₩17,320.00 | -4.04% |
| Precision BioSciences, Inc.NasdaqCM: DTIL | $180.24M | $6.53 | -2.83% |
| Hester Biosciences LimitedBSE: 524669 | $179.48M | Rs2,041.90 | -4.61% |
| Compass Therapeutics, Inc.NasdaqCM: CMPX | $178.83M | $0.94 | -5.59% |
| Cue Biopharma, Inc.NasdaqCM: CUE | $178.78M | $24.61 | -11.03% |
Figures last refreshed Oct 11, 2026.